Report Subject - Market Access - Page 1

Learn More What do Patients want from Pharma?: The Real Patient-Centric Perspective

What do Patients want from Pharma? How can pharma leverage patient insights to deliver the support they want? Is patient centricity coming of age? The patient voice is becoming increasingly influential and...

Compare
Learn More Biomarkers and Companion Diagnostics - Payer views

Winning Payer Support for Companion Diagnostics & Biomakers How can you positively influence payer attitudes to biomarkers and companion diagnostics (CDx)? Biomarkers and CDx are critical to realising the...

Compare
Learn More Real World Data: Meeting Payer Needs

How to adjust your Real World Data provision to address the real needs of payers Drug costs are spiralling upwards and so too are frustration levels. Payers with stretched budgets are still struggling to make the case...

Compare
Learn More How Payers Want to Work With Pharma

How to effectively engage US and EU payers You’re speaking to payers, but are they listening? Do you really understand their needs and concerns? Is your approach to payer negotiations getting your...

Compare
Learn More Pulling the Data Puzzle Together: Being Payer-Centric

Mapping data with payer needs. How to solve the data puzzle. Everyone is talking about data. What’s being collected; how robust is it; what does it prove; who should be told? From the all-important payer...

Compare
Learn More Charting the Orphan Drug Development Pipeline

Which are the most exciting areas of orphan drug research and where are the best opportunities? Global sales of drugs for orphan indications were estimated to be $114 billion in 2016, with sales forecast to rise to $209...

Compare
Learn More Real World Data Capabilities: Benchmarking Pharma Companies

Is Real World Data giving your market access the power charge it needs? Real World Data (RWD) and Real World Evidence (RWE) are gaining traction across the industry. The front runners are already exploring new ways to...

Compare
Learn More Overcoming Market Access Barriers to High Value Drugs

Overcoming market access barriers to high-value drugs How can you breakthrough the market access barriers that face high-value oncology and immunotherapy products in the EU5 and US? Pharma faces unprecedented demands...

Compare
Learn More Value Added Services: Payer Perspectives (2016)

Payer viewpoint: What should value-added services be providing? Getting close to payers and finding out exactly what they want from value-added services (VAS) has proved problematic for the pharmaceutical...

Compare
Learn More KAM Metrics: Measuring Success

Do you have the right metrics in place to know how well your KAM team is performing? A Key Account Management (KAM) approach has taken hold in pharma circles, but is it producing results? Plenty of resources have been...

Compare
Learn More Market Access and Commercial Excellence in Managed Markets

Commercial strategies for successful US managed market access Employ effective commercial strategies for optimal formulary position, pricing and reimbursement in US managed care markets. Healthcare reforms,...

Compare
Learn More Market Access Impact: Myeloma (US) 2016

Survey Results: Doctors say 5 major brands are losing market share due to prescription barriers We surveyed 100 US oncologists and haematologists to find out how market barriers affect the way they prescribe 9 myeloma...

Compare
Learn More Orphan Drug Market Access: Payer Insights on the Present and Future (2016)

How to ensure positive payer engagement for orphan drug market access The explosion in orphan drug approvals and high prices are causing increasing concern to payers. When there were few orphan drugs for small patient...

Compare
Learn More Market Access Impact: Non-Small Cell Lung Cancer (US) 2016

7 of the 10 brands we surveyed lose share due to market barriers. Is your brand one of them? In the US, market barriers are causing 7 of the 10 NSCLC drugs we surveyed to lose market share. What’s driving the top 3...

Compare
Learn More Market Access Impact: Type 2 Diabetes Mellitus (EU5) 2016

How are market barriers impacting the host of European T2DM brands? It’s a fact of life that non-clinical constraints such as cost, availability and administration are influencing prescribing trends for Type 2...

Compare
Learn More What is Value in Healthcare: The Payer Definition

How Pharma can meet payer’s expectations of value Payers want value, but what does that mean? Is it price, efficacy, safety, clinical outcomes, the patient view or wider health savings? With no consensus on the...

Compare
Learn More The Future of Market Access

What does the future hold for Market Access? The profile of Market Access (MA) departments is on the up. No longer simply existing as a ‘bolt on’ for other, more traditional activities, MA...

Compare
Learn More Patient Assistance Programs: Industry and Payer Perspectives (2016)

Patience Assistance Programmes: Achieving Stakeholder Buy in Patient Assistance Programmes (PAPs) help US patients financially and improve compliance, adherence and outcomes – what’s not to like? But many...

Compare
Learn More The Cost of Specialty Drugs: Payer Perspectives

Specialty drugs: Is the strain they are putting on healthcare budgets sustainable? US and EU healthcare budgets are under immense pressure as the cost of specialty medicines spirals inexorably upwards. This new report...

Compare
Learn More Customer Experience (CX) in Payer and Provider Engagement: How to Score Highly

It’s time to get serious about improving payer customer experience! Are payers and providers getting a positive experience from you? What kind of relationship or agreement works for them? What data do they...

Compare

Browse by

FirstWord Market Access Reports